A Registry for People With T-cell Lymphoma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 28, 2023

Keywords

ClinConnect Summary

This clinical trial is a registry study aimed at gathering information about various types of T-cell lymphoma, which is a group of cancers that affect a type of white blood cell called T-cells. By collecting data from patients, researchers hope to better understand these diseases and find ways to improve treatment outcomes. The study is currently recruiting participants of all ages and genders who have been diagnosed with specific types of T-cell or natural killer (NK) cell lymphomas, such as adult T-cell lymphoma or aggressive NK-cell leukemia.

To participate, individuals must provide consent and have a confirmed diagnosis supported by a tumor biopsy. Participants can expect to contribute to a valuable database that may help future patients with T-cell lymphoma. It's important to note that being part of this registry does not prevent you from participating in other clinical trials. If you're interested or think you might qualify, talking to your healthcare provider can help you understand more about your options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent
• • Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
• * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
• • T-cell prolymphocytic leukemia
• • T-cell large granular lymphocytic leukemia
• • Chronic lymphoproliferative disorder of NK cells
• • Aggressive NK-cell leukemia
• • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
• • Chronic active EBV infection of T- and NK-cell type, systemic form
• • Hydroa vacciniforme-like lymphoproliferative disorder
• • Adult T-cell leukemia/lymphoma
• • Extranodal NK/T-cell lymphoma, nasal type
• • Enteropathy-associated T-cell lymphoma
• • Monomorphic epitheliotropic intestinal T-cell lymphoma
• • Intestinal T-cell lymphoma, not otherwise specified (NOS)
• • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
• • Hepatosplenic T-cell lymphoma
• • Subcutaneous panniculitis-like T-cell lymphoma
• • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
• • Sézary syndrome
• • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
• • Primary cutaneous Gamma-Delta T-cell lymphoma
• • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
• • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
• • Peripheral T-cell lymphoma, not otherwise specified
• • Angioimmunoblastic T-cell lymphoma
• • Follicular T-cell lymphoma
• • Nodal peripheral T-cell lymphoma with TFH phenotype
• • Anaplastic large cell lymphoma, ALK-positive
• • Anaplastic large cell lymphoma, ALK-negative
• • Breast-implant associated anaplastic large cell lymphoma.
• • NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
• Exclusion Criteria:
• • Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
• • Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.